Tag Archives: ZIOP

No Comments

Blogging Options: CBOE Morning Update

Volatility as an asset class Ziopharm (ZIOP) is down $3.22 to $1.92 after announcing that its Phase 3 trial of palifosfamide for the treatment of metastatic soft tissue sarcoma in the first-line setting did not meet its primary endpoint. Overall option implied volatility of 209 is above its 26-week average of 122.